Latest news with #Tempus
Business Wire
4 days ago
- Business
- Business Wire
TEMPUS AI SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)-- Kahn Swick & Foti, LLC ('KSF') and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company's shares between August 6, 2024 and May 27, 2025, inclusive (the 'Class Period'). This action is pending in the United States District Court for the Northern District of Illinois. What You May Do If you purchased shares of Tempus and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( or visit to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 12, 2025. About the Lawsuit Tempus and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On May 28, 2025, Spruce Point Capital Management, LLC reported numerous issues with the Company's management, operations and financial reporting, including that: (i) Tempus CEO Eric Lefkofsky and his associates have a history cashing out of companies before public shareholders incur losses or lackluster returns; (ii) Tempus' actual AI capabilities are overstated; (iii) board members and other executives have been associated with troubled companies with restated financial results; (iv) signs of aggressive accounting and financial reporting are present; (v) there are issues with the AstraZeneca and Pathos AI deal that merit scrutiny; and (vi) the Company's recent financial guidance revision reveals weakness in core operations. On this news, the price of Tempus' shares fell $12.67 per share, or 19.23%, from a closing price of $65.87 per share on May 27, 2025, to a closing price of $53.20 per share on May 28, 2025. The case is Shouse v. Tempus AI. Inc., et al., No. 1:25-cv-06534. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit
Business Wire
4 days ago
- Business
- Business Wire
TEM Investors Have Opportunity to Lead Tempus AI, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tempus AI, Inc. ('Tempus' or 'the Company') (NASDAQ: TEM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 6, 2024 and May 27, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before August 12, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Tempus overinflated the value of various contracts including deals with related parties and self-funded agreements. The Company's joint venture with SoftBank was at risk of being discredited because of the appearance of 'round-tripping' capital to create revenue. The Company acquired Ambry, known for its aggressive and potentially unethical business practices. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Tempus, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
6 days ago
- Business
- Yahoo
Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach
ForTempus AI TEM, expanding partnerships with existing customers across each of its product lines is key to its growth. In April 2025, the AI-driven precision medicine company extended its collaboration with its earliest strategic client, AstraZeneca AZN. It teamed up with biotech company Pathos Inc. on a three-year, $200 million data and modeling license agreement. The three-way deal will build the largest multimodal foundation model in oncology, leveraging more than 300 petabytes of rich multimodal healthcare data that Tempus has built over the past decade. Notably, the deal raised the total remaining contract value to greater than $1 billion as of AstraZeneca, the partnership builds on its data and AI-driven R&D strategy, with the foundational model expected to speed up and increase the chances of clinical success across its broad pipeline. Meanwhile, Pathos is tapping into the growing trend of AI in drug discovery and development with this deal. Also in April, Tempus AI expanded its partnership with Illumina ILMN to help make molecular profiling part of the standard of care across more disease areas, including cardiology, neurology and immunology. Both Illumina and Tempus have a long-shared history of addressing gaps in testing, from pre-emptive screening and therapy selection to health economics and bioinformatics pipelines. Since molecular profiling is not yet standard across many disease areas and regions, patients often miss out on the benefits of precision medicine. Under this agreement, Tempus' multimodal data will enhance Illumina's AI-driven molecular analysis technologies, generating new insights that support the clinical value of sequencing. These will help create evidence packages needed to standardize the use of comprehensive genomic profiling and other molecular testing beyond cancer. The company also extended its commercial relationship with Personalis PSNL in December last year. After a strong response in the diagnostic market, Tempus now offers Personalis' NeXT Personal minimal residual disease (MRD) product to pharmaceutical and biotech customers. The strategic step allows Personalis to broaden market access of its ultra-sensitive MRD platform and leverage Tempus' integrated platform to serve biopharma customers who seek to bundle MRD testing with other Tempus products. Over the past year, Tempus AI shares have surged 77% compared with the industry's 39.7% growth. Image Source: Zacks Investment Research Tempus AI has a stretched valuation, with shares trading at a forward five-year Price-to-Sales (P/S) of 8.85X compared to the industry average of 6.34X. It carries a Value Score of F. Image Source: Zacks Investment Research Take a look at how the Zacks Consensus Estimate for Tempus AI's earnings has been revised over the past 90 days. Image Source: Zacks Investment Research TEM stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Illumina, Inc. (ILMN) : Free Stock Analysis Report Personalis, Inc. (PSNL) : Free Stock Analysis Report Tempus AI, Inc. (TEM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Business Wire
12-06-2025
- Health
- Business Wire
Tempus Announces Collaboration with Northwestern University's Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer's Disease Research
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine. This multi-year collaboration aims to harness AI for rapid discovery and innovation in Alzheimer's disease research. The collaboration leverages Tempus' AI-powered data analytics platform, Lens, to analyze and restructure the Center's repository of genomic data. Together, the Center and Tempus teams will work to uncover genomic patterns that have the potential to advance the understanding of Alzheimer's disease, investigate the gene and cell types affected, enable the development of new therapeutics, and accelerate the creation of novel clinical applications. By harnessing Lens' advanced AI capabilities, the collaboration aims to generate actionable insights that drive the discovery of targeted therapies and significantly improve patient outcomes. 'We are excited to collaborate with the Abrams Research Center on Neurogenomics to confront one of the most complex and pressing medical challenges of our time,' said Ryan Fukushima, Chief Operating Officer at Tempus. 'By integrating our AI platform with the Center's pioneering work in neurogenomics, we are opening new avenues for discovery. Together, we strive to advance research for Alzheimer's and bring hope and tangible impact to patients and families affected by this devastating disease.' 'This collaboration with Tempus represents an important step forward in our mission to harness cutting-edge technologies to transform Alzheimer's research,' said David Gate, PhD, assistant professor in Ken and Ruth Davee Department of Neurology at Feinberg and head of The Abrams Research Center on Neurogenomics. 'We share a commitment to deepen our understanding of the genomic underpinnings of Alzheimer's disease and accelerate the development of more targeted, effective interventions.' About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding the expected outcomes and benefits of the collaboration with the Abrams Research Center on Neurogenomics to advance research for Alzheimer's disease are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus' products and services; Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
Business Wire
02-06-2025
- Business
- Business Wire
Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced xM for treatment response monitoring (TRM), a liquid biopsy assay intended to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors. xM for TRM is the newest addition to Tempus' growing portfolio of sensitive assays for monitoring molecular response and minimal residual disease (MRD). It is currently available for research use only, with clinical availability expected later this year. In 2023, an estimated 56.55% of patients with advanced or metastatic cancers were eligible for ICIs, with a corresponding estimated response rate of 20.13%. 1 xM for TRM is designed to quantify changes in circulating tumor DNA (ctDNA) longitudinally from a blood sample, enabling early molecular response assessment in patients with advanced cancers receiving immunocheckpoint inhibitors (ICI) alone or combination therapies. xM for TRM leverages a unique multi-parametric algorithm, integrating copy number variations (CNVs), along with somatic and germline variant allele frequencies (VAFs), for a comprehensive and robust estimation of circulating tumor fraction. Tempus is presenting new data on xM for TRM at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, highlighting the assay's potential to help clinicians monitor response and refine treatment strategies for patients with advanced cancers. Title: A molecular biomarker for longitudinal monitoring of therapeutic efficacy in a real-world cohort of advanced solid tumors treated with immune checkpoint inhibitors Date/Time: Location: Poster Section Developmental Therapeutics—Immunotherapy (Poster #205) Overview: Tempus xM for TRM, a liquid biopsy test, monitors treatment response by tracking ctDNA dynamics over time. Longitudinal non-molecular responders are associated with worse survival compared to molecular responders, highlighting the value of xM molecular response monitoring as a tool to guide ICI treatment decisions. 'Our comprehensive monitoring portfolio is designed to support patients throughout the cancer treatment journey,' said Halla Nimeiri, MD, Chief Development Officer at Tempus. 'We're excited to introduce a new assay of molecular response for both physicians and biopharma researchers that can timely track changes of quantitative tumor fraction while patients receive ICI therapies. This may impact treatment decisions, especially for patients with advanced disease, where timing is absolutely critical. With xM for TRM, clinicians can detect molecular response to ICI prior to six weeks into treatment, enabling them to stay ahead of disease progression and optimize therapeutic strategies.' About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of xM TRM and other tests, the indicated use of the xM TRM and other tests for potential clinical use, and the timing of the availability of such testing, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
